423735-93-7

Basic information

• Product Name: ML 161
• Synonyms: ML 161;2-BroMo-N-[3-[(1-oxobutyl)aMino]phenyl]benzaMide;2-BroMo-N-(3-butyraMidophenyl)benzaMide;Benzamide, 2-bromo-N-[3-[(1-oxobutyl)amino]phenyl]-;ML 161 2-Bromo-N-[3-[(1-oxobutyl)amino]phenyl]benzamide;ML161, >=98%
• CAS NO: 423735-93-7
• Molecular Formula: C₁₇H₁₇BrN₂O₂
• Molecular Weight: 361.23308
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 423735-93-7.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 465.7±30.0 °C(Predicted)
• Appearance: white to beige/
• Density: 1.441±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• Solubility: DMSO: soluble5mg/mL (clear solution)
• PKA: 12.37±0.70(Predicted)
• CAS DataBase Reference: ML 161(CAS DataBase Reference)
• NIST Chemistry Reference: ML 161(423735-93-7)
• EPA Substance Registry System: ML 161(423735-93-7)

Safety Data

• RIDADR: UN 3077 9 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 423735-93-7(Hazardous Substances Data)

Usage

Description

ML 161 is an allosteric, reversible inhibitor of proteinase-activated receptor 1 (PAR1) on platelets, which selectively inhibits platelet activation. It is a diaminobenzene derivative that prevents the surface expression of P-selectin induced by the peptide SFLLRN with an IC50 value of 0.26 μM. ML 161 effectively blocks platelet activation induced by thrombin and SFLLRN, but not by PMA, U-46619, or collagen.

Uses

Used in Pharmaceutical Industry:
ML 161 is used as a selective inhibitor for platelet activation at protease-activated receptor 1 (PAR1) for the prevention and treatment of conditions related to excessive platelet activation, such as thrombosis and other clot-related disorders.
Used in Research Applications:
ML 161 is used as a research tool to study the role of PAR1 in platelet activation and thrombin-induced responses. It helps researchers understand the underlying mechanisms of platelet activation and develop new therapeutic strategies for related conditions.

references

[1]. dockendorff, c., et al., discovery of 1,3-diaminobenzenes as selective inhibitors of platelet activation at the par1 receptor. acs med chem lett, 2012. 3(3): p. 232-237.[2]. verplank, l., et al., chemical genetic analysis of platelet granule secretion-probe 3, in probe reports from the nih molecular libraries program. 2010, national center for biotechnology information (us): bethesda (md).

Upstream product

• 93469-29-5 3-butyrylaminoaniline 
• 88-65-3 2-bromobenzoic-acid 
• 107829-09-4 N-(3-nitrophenyl)butyramine 
• 99-09-2 3-nitro-aniline 

Relevant articles and documents

Compounds and methods for treating diseases mediated by protease activated receptors

The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.